- Home
- TXMD vs WDAY Comparison
TXMD vs WDAY Comparison
Compare TXMD & WDAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- WDAY
- Stock Information
- Founded
- TXMD 2008
- WDAY 2005
- Country
- TXMD United States
- WDAY United States
- Employees
- TXMD N/A
- WDAY N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- WDAY EDP Services
- Sector
- TXMD Health Care
- WDAY Technology
- Exchange
- TXMD Nasdaq
- WDAY Nasdaq
- Market Cap
- TXMD 13.5M
- WDAY N/A
- IPO Year
- TXMD N/A
- WDAY 2012
- Fundamental
- Price
- TXMD $1.17
- WDAY $225.27
- Analyst Decision
- TXMD
- WDAY Buy
- Analyst Count
- TXMD 0
- WDAY 27
- Target Price
- TXMD N/A
- WDAY $301.08
- AVG Volume (30 Days)
- TXMD 34.7K
- WDAY 2.4M
- Earning Date
- TXMD 08-11-2025
- WDAY 08-21-2025
- Dividend Yield
- TXMD N/A
- WDAY N/A
- EPS Growth
- TXMD N/A
- WDAY N/A
- EPS
- TXMD N/A
- WDAY 1.81
- Revenue
- TXMD $1,841,000.00
- WDAY $8,696,000,000.00
- Revenue This Year
- TXMD $427.09
- WDAY $14.87
- Revenue Next Year
- TXMD N/A
- WDAY $13.03
- P/E Ratio
- TXMD N/A
- WDAY $123.33
- Revenue Growth
- TXMD 53.55
- WDAY 14.95
- 52 Week Low
- TXMD $0.70
- WDAY $199.81
- 52 Week High
- TXMD $2.44
- WDAY $294.00
- Technical
- Relative Strength Index (RSI)
- TXMD 48.80
- WDAY 30.72
- Support Level
- TXMD $1.13
- WDAY $237.10
- Resistance Level
- TXMD $1.24
- WDAY $242.78
- Average True Range (ATR)
- TXMD 0.09
- WDAY 4.90
- MACD
- TXMD 0.01
- WDAY -1.26
- Stochastic Oscillator
- TXMD 76.92
- WDAY 9.43
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.